Stephen Johnson

Array ( [id] => 19232161 [patent_doc_number] => 20240189352 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-13 [patent_title] => T-CELL RECEPTORS SPECIFIC FOR BOTH RAC1- AND RAC2-DERIVED MUTATED EPITOPES [patent_app_type] => utility [patent_app_number] => 18/286933 [patent_app_country] => US [patent_app_date] => 2022-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17529 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 142 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18286933 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19246888 [patent_doc_number] => 20240197872 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-20 [patent_title] => NOVEL COMPOSITIONS ENRICHED IN GAMMA DELTA T CELLS, METHODS OF PREPARATION, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/286286 [patent_app_country] => US [patent_app_date] => 2022-04-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47991 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -57 [patent_words_short_claim] => 41 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18286286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18693064 [patent_doc_number] => 20230323451 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => Selective amplification of molecularly identifiable nucleic 5 acid sequences [patent_app_type] => utility [patent_app_number] => 17/714780 [patent_app_country] => US [patent_app_date] => 2022-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 42576 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 13 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17714780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17895834 [patent_doc_number] => 20220305496 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-29 [patent_title] => METHODS AND COMPOSITIONS FOR DETECTING TARGET NUCLEIC ACIDS AND RESOLVING SAMPLE MATRICES [patent_app_type] => utility [patent_app_number] => 17/696452 [patent_app_country] => US [patent_app_date] => 2022-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28707 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17696452 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17868486 [patent_doc_number] => 20220291222 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => EXTRACELLULAR VESICLE BIOMARKERS FOR PANCREATIC CANCER DETECTION, DIAGNOSIS AND MONITORING [patent_app_type] => utility [patent_app_number] => 17/692377 [patent_app_country] => US [patent_app_date] => 2022-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7430 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17692377 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20279416 [patent_doc_number] => 20250304658 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-02 [patent_title] => NEUTRALIZING MONOCLONAL ANTIBODIES TO BK VIRUS [patent_app_type] => utility [patent_app_number] => 18/549974 [patent_app_country] => US [patent_app_date] => 2022-03-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20614 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18549974 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18194837 [patent_doc_number] => 20230048356 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-16 [patent_title] => CELL BARCODING COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 17/692100 [patent_app_country] => US [patent_app_date] => 2022-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 78814 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17692100 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19599602 [patent_doc_number] => 20240390482 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-28 [patent_title] => HIV-1 ENVELOPE GLYCOPEPTIDE NANOPARTICLES AND THEIR USES [patent_app_type] => utility [patent_app_number] => 18/280935 [patent_app_country] => US [patent_app_date] => 2022-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17532 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18280935 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19613237 [patent_doc_number] => 20240398917 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-05 [patent_title] => COMPOSITIONS AND METHODS FOR PREVENTING TUMORS AND CANCER [patent_app_type] => utility [patent_app_number] => 18/272329 [patent_app_country] => US [patent_app_date] => 2022-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27829 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -36 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18272329 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18955163 [patent_doc_number] => 20240043490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-08 [patent_title] => TARGETED CYTOKINE CONSTRUCT FOR ENGINEERED CELL THERAPY [patent_app_type] => utility [patent_app_number] => 18/256512 [patent_app_country] => US [patent_app_date] => 2021-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54897 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -165 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18256512 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18939651 [patent_doc_number] => 20240034790 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-01 [patent_title] => ANTIBODY SPECIFIC FOR CD47 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/256172 [patent_app_country] => US [patent_app_date] => 2021-12-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12081 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 671 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18256172 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19051180 [patent_doc_number] => 20240093149 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => MODIFIED T CELLS FOR ADOPTIVE IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 18/039868 [patent_app_country] => US [patent_app_date] => 2021-12-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5318 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18039868 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18877469 [patent_doc_number] => 20240000838 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => UNIVERSAL CHIMERIC ANTIGEN RECEPTOR-EXPRESSING IMMUNE CELLS FOR ALLOGENEIC CELL THERAPY [patent_app_type] => utility [patent_app_number] => 18/255095 [patent_app_country] => US [patent_app_date] => 2021-11-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12134 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18255095 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18893833 [patent_doc_number] => 20240009318 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-11 [patent_title] => MODIFIED EGFR ANTIBODY WITH REDUCED AFFINITY, DRUG CONJUGATE, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/253681 [patent_app_country] => US [patent_app_date] => 2021-11-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6491 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18253681 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18877591 [patent_doc_number] => 20240000960 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-04 [patent_title] => ANTI-CD6 ANTIBODY CONJUGATES FOR TREATING T-CELL MEDIATED DISORDERS AND T-CELL LYMPHOMA/LEUKEMIA [patent_app_type] => utility [patent_app_number] => 18/252928 [patent_app_country] => US [patent_app_date] => 2021-11-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8924 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18252928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20218690 [patent_doc_number] => 20250281621 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-11 [patent_title] => GPC3 APTAMERS AND VARIANTS AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/252763 [patent_app_country] => US [patent_app_date] => 2021-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12081 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18252763 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18860226 [patent_doc_number] => 20230414660 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => PD-1 DECOY VARIANTS FOR IMMUNOTHERAPY [patent_app_type] => utility [patent_app_number] => 18/252379 [patent_app_country] => US [patent_app_date] => 2021-11-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27040 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18252379 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17595383 [patent_doc_number] => 20220144956 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-12 [patent_title] => HETERODIMERIC ANTIBODIES THAT BIND TGFbetaRII [patent_app_type] => utility [patent_app_number] => 17/520590 [patent_app_country] => US [patent_app_date] => 2021-11-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53655 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17520590 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18817517 [patent_doc_number] => 20230391857 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => METHODS OF TREATING INFECTIONS BY BLOCKING PATHOGEN MIMICS OF CD47 [patent_app_type] => utility [patent_app_number] => 18/034026 [patent_app_country] => US [patent_app_date] => 2021-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11568 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18034026 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18817519 [patent_doc_number] => 20230391859 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => ANTI-TRANSTHYRETIN ANTIBODIES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/033568 [patent_app_country] => US [patent_app_date] => 2021-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35429 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18033568 [rel_patent_id] =>[rel_patent_doc_number] =>)